Literature DB >> 8475991

A 34-kd protein with strong homology to ras-like proteins inhibits epidermal growth factor activity.

D S Strayer1, J Mathew.   

Abstract

Epidermal growth factor (EGF) and its analog, transforming growth factor-alpha, are felt to be important in oncogenesis. When malignant rabbit fibroma virus infects RK-13 rabbit kidney cells, a 34-kd protein that inhibits the effects of EGF on certain target cell lines is produced. We have purified this protein using high-pressure liquid chromatography and gel electrophoresis. This purified protein abolishes EGF-induced cellular proliferation. It also causes the EGF receptor-bearing A431 carcinoma cell line to stop proliferating in vitro. This purified 34-kd EGF inhibitor (EGFI) redirects cellular protein phosphorylation in the presence or absence of EGF. Whereas EGF increases phosphorylation of cellular proteins in normal rat kidney cells, clone 49F, and A431 EGFI generally decreases it. Both EGF and EGFI cause increased protein production in A431 and normal rat kidney cells. The major species of protein synthesized by cells seem invariant to EGFI, with or without EGF. The partial protein sequence of two fragments of EGFI shows striking similarity to two ras like proteins. Possible means by which such a ras-like protein might inhibit EGF-induced cellular proliferation are discussed. Therefore, a purified 34-kd ras-like protein inhibits EGF-induced cellular proliferation and changes the targets for cellular protein phosphorylation. Studies are in progress to characterize this protein further, both structurally and functionally.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8475991      PMCID: PMC1886867     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  Determinants of virus-related suppression of immune responses as observed during infection with an oncogenic poxvirus.

Authors:  D S Strayer
Journal:  Prog Med Virol       Date:  1992

2.  Purification and characterization of vaccinia virus growth factor.

Authors:  P Stroobant; A P Rice; W J Gullick; D J Cheng; I M Kerr; M D Waterfield
Journal:  Cell       Date:  1985-08       Impact factor: 41.582

3.  Inhibition of epidermal growth factor-induced cellular proliferation.

Authors:  D S Strayer; J L Leibowitz
Journal:  Am J Pathol       Date:  1987-08       Impact factor: 4.307

4.  Epidermal growth factor precursor is related to the translation product of the Moloney sarcoma virus oncogene mos.

Authors:  G S Baldwin
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

5.  Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells.

Authors:  A Ullrich; L Coussens; J S Hayflick; T J Dull; A Gray; A W Tam; J Lee; Y Yarden; T A Libermann; J Schlessinger
Journal:  Nature       Date:  1984 May 31-Jun 6       Impact factor: 49.962

6.  Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes.

Authors:  P Matsudaira
Journal:  J Biol Chem       Date:  1987-07-25       Impact factor: 5.157

7.  Epidermal growth factor receptors on corneal endothelium.

Authors:  R N Fabricant; A J Alpar; Y M Centifanto; H E Kaufman
Journal:  Arch Ophthalmol       Date:  1981-02

8.  Malignant rabbit fibroma virus causes secondary immunosuppression in rabbits.

Authors:  D S Strayer; E Skaletsky; G F Cabirac; P A Sharp; L B Corbeil; S Sell; J L Leibowitz
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

9.  Autophosphorylation sites on the epidermal growth factor receptor.

Authors:  J Downward; P Parker; M D Waterfield
Journal:  Nature       Date:  1984 Oct 4-10       Impact factor: 49.962

10.  Vaccinia virus-infected cells release a novel polypeptide functionally related to transforming and epidermal growth factors.

Authors:  D R Twardzik; J P Brown; J E Ranchalis; G J Todaro; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.